Nurix TherapeuticsNRIX
About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Employees: 284
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 18
79% more capital invested
Capital invested by funds: $756M [Q1] → $1.36B (+$601M) [Q2]
33% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 45
26% more funds holding
Funds holding: 137 [Q1] → 173 (+36) [Q2]
4.38% more ownership
Funds ownership: 105.2% [Q1] → 109.58% (+4.38%) [Q2]
54% less call options, than puts
Call options by funds: $1.05M | Put options by funds: $2.28M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Needham Gil Blum 42% 1-year accuracy 40 / 95 met price target | 14%upside $29 | Buy Reiterated | 21 Oct 2024 |
HC Wainwright & Co. Robert Burns 46% 1-year accuracy 66 / 145 met price target | 18%upside $30 | Buy Maintained | 21 Oct 2024 |
RBC Capital Gregory Renza 66% 1-year accuracy 41 / 62 met price target | 3%upside $26 | Outperform Maintained | 14 Oct 2024 |
Stephens & Co. Sudan Loganathan 0% 1-year accuracy 0 / 1 met price target | 22%upside $31 | Overweight Reiterated | 14 Oct 2024 |
Needham Gil Blum 42% 1-year accuracy 40 / 95 met price target | 14%upside $29 | Buy Reiterated | 14 Oct 2024 |
Financial journalist opinion
Based on 8 articles about NRIX published over the past 30 days
